Dasatinib, a dual Src and abl tyrosine kinase inhibitor, has recently been approved in Philadelphia (Ph) chromosome, Ph-positive chronic myeloid leukaemia (CML) and Ph-positive acute lymphoblastic leukaemia with resistance or intolerance to imatinib mesylate. 1 Until now, discontinuation of imatinib in CML patients has always been associated with further disease recurrence, except in a few patients with undetectable bcr-abl transcripts. 2 For the first time, we report on a CML patient treated with dasatinib after imatinib resistance, who maintained low levels of bcr-abl transcripts despite dasatinib discontinuation.
The patient was diagnosed with chronic-phase CML in August 2001 at the age of 53 years. On diagnosis, this patient lacked cytogenetic evidence of the Ph chromosome, but the bcr-abl rearrangement, the molecular hallmark of CML, was identified by both fluorescent in situ hydridization and reverse transcription-PCR techniques, with the presence of b3a2-type transcripts. He received hydroxyurea alone until progression towards an acute myeloblastic phase of the disease in December 2003. At the time of progression, an abnormal karyotype was found with a 45,XY,-7,der(19)t(7;19)(q21;p13) in 20 metaphases. The bcr-abl rearrangement was detected by fluorescent in situ hydridization in 100% of interphase cells (500 nuclei analysed). The bcr-abl/abl internationally standardized (IS) transcript ratio was 47% (Figure 1) . A complete haematological response, a normal karyotype and a residual disease down to 0.27% ( Figure 1 ) were obtained after two courses of induction chemotherapy with daunorubicine and cytarabine combined with imatinib at 600 mg daily. No suitable human leukocyte antigen-matched donor was found, and the patient was maintained on single-agent imatinib.
In December 2004, a relapse of myeloblastic-phase CML occurred. Karyotype analysis revealed abnormalities identical to those observed at the time of the first blast crisis. The bcr-abl rearrangement was present in 100% of interphase cells by fluorescent in situ hydridization, and the bcr-abl/abl IS transcript ratio increased to 42% (Figure 1) . A mutational analysis of the tyrosine kinase domain of abl performed by PCR and direct sequencing revealed an Y253H mutation located in the adenosine triphosphate-binding loop (P-Loop) of the bcr-abl oncoprotein that confers a high degree of resistance to imatinib. 3 Imatinib was stopped and the patient was started on single-agent dasatinib at 70 mg twice daily in January 2005. The dosage of dasatinib was decreased rapidly to 50 mg twice daily due to a grade 2 pleural effusion and gastrointestinal intolerance. A complete haematological response, a normal karyotype and a major molecular response (bcr-abl/abl IS ratio p0.1%) were obtained after 2 months of dasatinib treatment. After 10 months of continuous treatment, major molecular response proved to be stable with a bcr-abl/abl IS transcript ratio down to 0.04% (Figure 1 ). The decision was made to collect an autologous peripheral blood stem cell graft and the patient 
twice a day for five consecutive days under dasatinib therapy. On day 5, the peripheral blood CD34 þ cell concentration was 54.8/mm 3 . Apheresis was carried out using a Cobe Spectra cell separator (Gambro BCT, Stokholm, Sweden), and a cellular product containing 6.86 Â 10 8 nucleated cells/kg, 5.55 Â 10 6 CD34 þ cells/kg and 173.3 Â 10 4 granulocytemacrophage colony-forming unit/kg was harvested and cryopreserved, the bcr-abl/abl IS ratio in the graft being 0.09%. The decision to proceed to an autologous stem cell transplantation was thus taken. Dasatinib treatment ceased at the start of the conditioning regimen consisting of intravenous busulfan and cyclophosphamide. Autologous peripheral blood stem cell transplantation was carried out in January 2006. After thawing, cell viability was 92% and the infused product contained 4.6 Â 10 8 viable nucleated cells/kg and 4.6 Â 10 6 viable CD34 þ cells/kg. Neutrophil and platelet recovery was obtained within 17 days without any granulocyte colony-stimulating factor treatment and no severe documented infection occurred. Dasatinib was not reintroduced. At the last follow-up in June 2008, the patient remained in complete haematological response with a normal karyotype and a stable residual disease measured at 0.01%, in the absence of any tyrosine kinase inhibitor therapy (Figure 1 ). Gabriel et al. 4 recently reported on one chronic-phase CML patient responding to dasatinib after imatinib resistance, in whom dasatinib combined with granulocyte colony-stimulating factor was effective for peripheral mobilization and collection of CD34 þ cells. Here, we do not only show that we were able to successfully collect and cryopreserve a highquality autologous peripheral blood stem cell graft containing low levels of residual disease under dasatinib, but also show that dasatinib treatment before and during CD34 þ cell mobilization and collection did not impair haematopoietic recovery after transplantation. Finally, the most remarkable finding resides in a stable major molecular response despite the cessation of dasatinib therapy.
We could not investigate on possible mechanisms involved in the maintenance of low residual disease levels in the absence of tyrosine kinase inhibitor therapy in this patient, and we do not widely recommend dasatinib discontinuation at the present time. Nevertheless, our observation suggests that autologous haematopoietic stem cell transplantation in patients responding to dasatinib after imatinib resistance may be a viable therapeutic option for advanced-phase CML patients not eligible for allogeneic transplantation or those lacking a human leukocyte antigen-matched donor. Whether maintenance therapy with dasatinib is required in patients with low levels of residual disease after transplantation should be assessed in the setting of a clinical trial. Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. CLL can be classified into two biological subtypes, according to the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgV H ). IgV H mutational status is of high-clinical relevance: cases with unmutated IgV H show a less favorable course with a rapid progression, whereas cases with mutated IgV H show a stable disease and longer survival. Unfavorable prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years.
MicroRNAs (miRNAs) are short B22 nucleotide long RNA molecules that function as specific regulators of the gene expression with an essential role in cell proliferation, differentiation, apoptosis, chromosome structure and virus resistance.
